Gastroenterology Disease and Lifestyle Medicine

  • Gerald FriedmanEmail author


Lifestyle medicine, emphasizing prevention as well as therapy, plays a central role in the understanding and treatment of gastrointestinal (GI) illnesses. This chapter will focus upon specific GI diseases associated with clinical symptoms related to disturbed immune function. Attention will be directed to the pathophysiologic underpinning of the disease process and the role of lifestyle applications preventing or ameliorating the illness. Such consideration will be given to GI reflux disease, peptic ulcer and gastritis, gall bladder disease, pancreatitis, Celiac disease, irritable bowel syndrome, and inflammatory bowel diseases.


GERD (gastroesophageal reflux disease) PUD (peptic ulcer disease) IBD (inflammatory bowel disease) UC (ulcerative colitis) CD (Crohn’s disease) Microbiome IBS (irritable bowel disease) 



Attention deficit hyperactivity disorder


Body Mass Index


Crohn’s disease




Deoxyribonucleic acid




Fluorescence in situ hybridization


Fermentable oligo-, di- and mono-saccharides and polyols


Gastroesophageal reflux disease




Human immunodeficiency virus


Inflammatory bowel diseases


Irritable bowel syndrome


Lower esophageal sphincter


Non-celiac gluten sensitivity


Nonsteroidal anti-inflammatory agents

n-3 FA

Omega-3 fatty acids

n-6 FA

Omega-6 fatty acids


Polymerase chain reaction


Polyunsaturated fatty acids


Registered dietitian


Ribonucleic acid


Short-chain fatty acids


Tissue transglutaminase


Tissue transglutaminase immunoglobulin A


Transient lower esophageal sphincter relaxations


Terminal restriction fragment length polymorphism


Ulcerative colitis


Ursodeoxycholic acid


  1. 1.
    El-Serag HB, Ergun GA, Pandolfino J, et al. Obesity increases oesophageal acid exposure. Gut. 2007;56:749–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;2:1311–5.CrossRefGoogle Scholar
  3. 3.
    Lee SA, Kang D, Shim KN, et al. Effect of diet and Helicobacter pylori infection to the risk of early gastric cancer. J Epidemiol. 2003;13:162–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Allison MC, Howaston AG, Torrance CJ, et al., Gastrointestinal damage associated with the use of non-steroidal anti-inflammatory drugs. N Engl J Med. 1992;327:749–54.CrossRefPubMedGoogle Scholar
  5. 5.
    Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gall bladder disease in the United States. Gastroenterology. 1999;117:632–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Heaton KW, Braddon FE, Mountford RA, et al. Symptomatic and silent gallstones in the community. Gut. 1991;32:316–20.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ransohoff DF, Gracie WA, Wolfenson LB, Neuhauser D. Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. Ann Int Med. 1983;99:199–204.CrossRefPubMedGoogle Scholar
  8. 8.
    Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20:981–96.CrossRefPubMedGoogle Scholar
  9. 9.
    Badalov N, Baradarian R, Iswara K, et al. Drug-induced pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007;5:648–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Forsmark CE, Baillie J. AGA Institute Councl Practice and Economics Committee, AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022.CrossRefPubMedGoogle Scholar
  11. 11.
    Otsuki M, Tashiro M. Chronic pancreatitis and pancreatic cancer, lifestyle-related diseases. Intern Med. 2007;46:109–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Rostom A, Murray JA, Kagnoff ME. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology. 2006;131:l981–2002.CrossRefGoogle Scholar
  13. 13.
    Mansueto P, Seidita A, D’Alcamo A, Carroccio A. Non-celiac gluten sensitivity: literature review. J Am Coll Nutr. 2014;33(1):39–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Brandt LJ, Chey WD, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104 Suppl 1:S1.CrossRefPubMedGoogle Scholar
  15. 15.
    Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome. Am J Gastroenterol. 2001;96:1499–506.CrossRefPubMedGoogle Scholar
  16. 16.
    Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53:1096–101.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Jeffery IB, O’Toole PW, Ohman L, et al. An irritable bowel subtype defined by species specific alterations in faecal microbiota. Gut. 2012;61:997–1006.CrossRefPubMedGoogle Scholar
  19. 19.
    Chey WD. The role of food in the functional gastrointestinal disorders: introduction to a manuscript series. Am J Gastroenterol. 2013;108:694–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Gibson PR, Shepherd SJ. Food choice as a key management strategy for functional gastrointestinal symptoms. Am J Gastroenterol. 2012;107:657–66.CrossRefPubMedGoogle Scholar
  21. 21.
    Amre AK, D’souza S, Morgan K, Seidman G, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol. 2007;102:2016–25.CrossRefPubMedGoogle Scholar
  22. 22.
    Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563–73.CrossRefPubMedGoogle Scholar
  23. 23.
    Nagalingam NA, Lynch SV. Role of microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:968–80.CrossRefPubMedGoogle Scholar
  24. 24.
    Sekirov I, Russell SL, Atunes CM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904.CrossRefPubMedGoogle Scholar
  25. 25.
    Tannock GW. New Perceptions of the gut microbiota: implications for future research. Gastroenterol Clin N Am. 2005;41:361–82.CrossRefGoogle Scholar
  26. 26.
    Chatterjess S, Kar P, Das T, et al. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and bifidobacterium BB-12 for prevention of antibiotic-associated diarrhea. J Assoc Physicians India. 2013;61:708–12.Google Scholar
  27. 27.
    Abbas Z, Yakoob J, Jafri W, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol. 2014;26:630–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Ailment Pharmacol Ther. 2014;39:1113–25.CrossRefGoogle Scholar
  29. 29.
    Aoki T, Asahara T, Matsumoto K, et al. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol. 2014;49:552–63.CrossRefPubMedGoogle Scholar
  30. 30.
    Hegar B, Hutapea EI, Advani N, et al. A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole. J Pediatr. 2013;89:381–7.CrossRefGoogle Scholar
  31. 31.
    Shao F, Xin FZ, Yang CG, et al. The impact of microbial immune enteral nutrition on the patients with acute radiation enteritis in bowel function and immune status. Cell Biochem Biophys. 2014;69:357–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Virk A, Mandrekar J, Berbari EF, et al. A randomized, double blind, placebo-controlled trial of an oral symbiotic (AKSB) for prevention of travelers’ diarrhea. J Travel Med. 2013;20:88–94.CrossRefPubMedGoogle Scholar
  33. 33.
    Woodward GA, Encarnacion B, Downey JR, et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J Gastrointest Surg. 2009;13:1198–204.CrossRefGoogle Scholar
  34. 34.
    Mekkes MC, Weenen TC, Brummer RJ, et al. The development of probiotic treatment in obesity: a review. Benef Microbes. 2014;5:19–28.CrossRefPubMedGoogle Scholar
  35. 35.
    Gomes AC, Bueno AA, de Souza RG, et al. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13:60. doi:10.1186/1475-2891-13-60.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of GastroenterologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations